title: Pharmacogenomically actionable medications in a safety net health care system.
abstract: OBJECTIVE
  Prior to implementing a trial to evaluate the economic costs and clinical outcomes of pharmacogenetic testing in a large safety net health care system, we determined the number of patients taking targeted medications and their clinical care encounter sites.
  
  
  METHODS
  Using 1-year electronic medical record data, we evaluated the number of patients who had started one or more of 30 known pharmacogenomically actionable medications and the number of care encounter sites the patients had visited.
  
  
  RESULTS
  Results showed 7039 unique patients who started one or more of the target medications within a 12-month period with visits to 73 care sites within the system.
  
  
  CONCLUSIONS
  Findings suggest that the type of large-scale, multi-drug, multi-gene approach to pharmacogenetic testing we are planning is widely relevant, and successful implementation will require wide-scale education of prescribers and other personnel involved in medication dispensing and handling.
authors.affiliation: Department of Science of Nursing Care, School of Nursing, Indiana University, Indianapolis, IN, USA.
authors.forename: Janet S
authors.initials: JS
authors.lastname: Carpenter
authors.affiliation: Department of Pediatrics, Indiana University, Indianapolis, IN, USA.
authors.forename: Marc B
authors.initials: MB
authors.lastname: Rosenman
authors.affiliation: Department of Science of Nursing Care, School of Nursing, Indiana University, Indianapolis, IN, USA.
authors.forename: Mitchell R
authors.initials: MR
authors.lastname: Knisely
authors.affiliation: Department of Medicine, Indiana University, Indianapolis, IN, USA.
authors.forename: Brian S
authors.initials: BS
authors.lastname: Decker
authors.affiliation: Department of Medicine, Indiana University, Indianapolis, IN, USA.
authors.forename: Kenneth D
authors.initials: KD
authors.lastname: Levy
authors.affiliation: Department of Medicine, Indiana University, Indianapolis, IN, USA.
authors.forename: David A
authors.initials: DA
authors.lastname: Flockhart
keywords: Pharmacoepidemiology; genetic polymorphism; genotype; patient safety; pharmacogenetics; pharmacogenomics
references.citation: Ann Pharmacother. 2008 Jul;42(7):1017-25
references.pmid: 18594048
references.citation: Psychosom Med. 2013 Apr;75(3):311-6
references.pmid: 23533282
references.citation: Mayo Clin Proc. 2013 Jul;88(7):697-707
references.pmid: 23790544
references.citation: Nat Rev Drug Discov. 2009 Apr;8(4):279-86
references.pmid: 19300459
references.citation: Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):56-67
references.pmid: 24616371
references.citation: Annu Rev Pharmacol Toxicol. 2015;55:89-106
references.pmid: 25292429
references.citation: Breast Cancer Res Treat. 2011 Apr;126(2):529-37
references.pmid: 20803066
references.citation: Clin Pharmacol Ther. 2012 Aug;92(2):235-42
references.pmid: 22739144
references.citation: J Urban Health. 2009 Mar;86(2):230-41
references.pmid: 19082899
references.citation: JRSM Cardiovasc Dis. 2012 Apr 05;1(1):null
references.pmid: 24175062
references.citation: Ann Surg Oncol. 2013 Apr;20(4):1142-7
references.pmid: 23334252
references.citation: Pharmacogenomics. 2013 Feb;14(3):325-34
references.pmid: 23394394
references.citation: Pharmacotherapy. 2006 May;26(5):601-8
references.pmid: 16637789
references.citation: Asian Pac J Cancer Prev. 2013;14(4):2259-63
references.pmid: 23725123
references.citation: J Womens Health (Larchmt). 2008 Sep;17(7):1081-92
references.pmid: 18774893
references.citation: Clin Pharmacol Ther. 2012 Mar;91(3):450-8
references.pmid: 22278335
references.citation: Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):68-75
references.pmid: 24616296
references.citation: Oncology. 2006;71(1-2):1-9
references.pmid: 17344666
references.citation: N Engl J Med. 2003 Feb 6;348(6):538-49
references.pmid: 12571262